Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D

(MedPage Today) -- Pemvidutide (2.4 mg), an investigational GLP-1/glucagon dual receptor agonist, helped people with obesity achieve an average 15.6% weight loss after 48 weeks in the phase II MOMENTUM trial, developer Altimmune announced. Meanwhile...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news